Diseases of affluence (of the 21st c.) by definition should have higher prevalence and/or mortality rates in richer and more developed countries than in poorer, underdeveloped states (where diseases of poverty are more common). Therefore, it has been indicated that it is civilizational progress that makes us sick. On the other hand, substantial financial resources, highly qualified medical personnel, and the cutting-edge technology of richer states, should allow for effective preventions, diagnostics, and treatment of diseases of poverty and of affluence. Therefore, a dilemma arises: is progress making us sick or curing us? To evaluate the influence of country socioeconomic and technological development on population health, a spatial analysis of the epidemiology of diseases of affluence and distribution of economic resources for European NUTS 2 has been performed. The main aim of this paper is to assess, how regional diversity in the prevalence of diseases of affluence is related to the regional development of regions.
Introduction
For centuries, fatal and communicable diseases like the "Black death" created havoc across Europe. (Haensch et al., 2010; Scott, Duncan, 2007 ) Today, we are incomparably much more knowledgeable in many aspects of the microbiology and epidemiology of transmittable diseases. However, the knowledge we have is not enough in eradicating all the possible "plagues". The Asian SARS epidemic in 2003 and lasting since 2013 the Ebola virus epidemic in West Africa is proof of that (Scott, Duncan, 2007; Cook, Halsall 2012) . Nevertheless, the most communicable diseases are typical epidemic problems in poorer regions, so they are rather perceived as diseases of poverty than affluence.
Diseases of affluence, also known as diseases of the 21st c., Western diseases or in Polish
civilizational diseases, have been defined as diseases with higher prevalence and/or mortality rates in richer and more developed countries than in poorer, underdeveloped states, where on the contrary diseases of poverty are more common. Therefore, it has been indicated that it is civilizational progress that makes us sick. The affluence hypothesis has been stated on numerous occasions suggesting the undesirable medical effect of progress: over time, across regions, or income groups, both in a macro and micro scale. It can be summarized that: the more affluent (wealthy, developed etc.) the object (country, region, social group, household, person etc.) Chan, Bloomberg, 2016) . The economic factor is also crucial. Health economics states that the relationship between economy and health, both in a micro and macro scale, are strong and bidirectional. Too low expenditures on health care cause a deterioration of public health, which in consequence results in the decrease of productivity, greater absenteeism, and loss-of-life costs (Frenk, 2004; Żółtaszek, Budny, 2016) . On the other hand, socioeconomic and technological development brings drastic changes in lifestyles (e.g. less physical activity, unbalanced diet), environmental degradation and chemical enhancements in food and cosmetics, which may cause or stimulate additional medical issues (Aue, 2009; Bender, 2015; Campbell, Campbell, 2013; Cook, Halsall, 2012; Ferrante, 2014; Roik 2008) .
Nowadays, cardiovascular problems (one of the main diseases of affluence) are a major cause of death in developed countries leading to over 30% of all deaths (for instance in 2013: 37% for the EU 28, 40% in Germany, 46% in Poland, up to 65% in Bulgaria -see Eurostat database). (WHO Cardiovascular diseases, WHOGlobal Health Observatory) There is no standardized list of disease of affluence. However, it is often indicated that they include: cardiovascular diseases, respiratory system diseases, cancer, obesity, diabetes, allergies, mental disorders, and HIV (which has some characteristics of both diseases of poverty and affluence) (Ferrante, 2014; Kotarski, 2013; Roik, 2008) . The growing global problem with these noncommunicable diseases is a fact. However, there is no irrefutable evidence that the prevalence of these afflictions is stimulated by economic and social development. It is generally believed that regions with higher economic indicators are more at risk, than poorer ones. They are considered to be the cost and by-product of social, cultural, technological, and economic progress in highly developed societies (Kotarski, 2013; Link, 2007; Aue, 2009 ). Most of these are chronic diseases, which mean that their duration exceeds 3 to 6 months (depending on the source of the definition) or even extends to whole life. Very often, the period of development of the diseases is also typically large (WHO Non communicable; Ferrante, 2014) . However, no clear spatial patterns have been confirmed. Proving or disproving some of the common notions could be very beneficial for developing and assessing regional, international, and global policies on the diseases of the 21stI c.
On the other hand, substantial financial resources, highly qualified medical personnel, and the cutting-edge technology of richer states, should favour effective prevention, diagnostics, and treatment of both, diseases of poverty and diseases of affluence. Therefore, a question arises: is progress making us sick or curing us? To evaluate the influence of a country's socioeconomic and technological development on population health, a spatial analysis of epidemiology of diseases of affluence and distribution of economic resources has been performed. The main aim of this paper is to assess, how regional diversity in the prevalence of diseases of affluence is related to the level of development of regions. Żółtaszek, Budny, 2016) . However, in each case the hypothesis of affluence influencing prevalence has been rising in some way. Often the association between wealth and illnesses is suggested by medical doctors based on their knowledge and experience and not objective spatiotemporal data analysis. The statistical approach could finally prove or disprove the existence of diseases of affluence. Yet lacking comparable data makes it very difficult or even impossible. There are limited data on the prevalence of each illness with: (1) a time series long enough to verify the hypothesis and (2) spatial data (not only by country but by smaller regions) for worldwide comparisons. Usually the available information on diseases of affluence states the mortality rates (based on cause of death) which does not reflect the prevalence. Firstly, people suffer from a certain disease do not necessarily die because of it. They can be killed in accidents, by other illnesses, or murdered. Especially in high-income countries with good healthcare systems and modern medicine, most diseases of affluence can be cured or managed elongating the expected lifespan, which increases the probability of different causes of death. Secondly, if the affluence hypothesis is true and wealth (for example GDP per capita, income per household member) causes a higher frequency of becoming ill or more severe symptoms there may be another effect in an opposite direction: (1) the richer country, region, person, or household, the higher expenditures on health (public, private, and total); (2) the higher the medical expenses, the better the health care in aspect of accessibility, diagnostics, technology, human resources; (3) the better health care, the lower mortality of any medical cause including diseases of affluence.
Therefore even if affluence may cause higher prevalence it may as well lower the mortality of diseases of the 21st c. Thus, mortality statistics may be underestimated as a measurement of prevalence due to both factors. Moreover the "double-aged sword" of affluence makes it difficult to "guess" which effect is stronger and is the tendency constant over time, space, and disease. Analysing spatial patterns of mortality due to each illness and their dependence with economic progress may not give any final proof of the existence of diseases of affluence and solve all of the connected problems. It will, however, deliver crucial insight into the mystery of the diseases of affluence.
The paper is structured as follows. Section 2 introduces some of the methodology used in the study and the results of our empirical analysis. Finally, Section 3 provides a summary and some concluding remarks.
Methodology and Empirical Analysis
To assess the regional influence of economic progress on the state of population health some spatial analysis tools were employed. The research was carried out on NUTS 2 1 European Union regional level based countries on the Eurostat dataset (Eurostat database). The data used made it possible to evaluate the influence of economic factors as well as recognize some spatial patterns of prevalence and mortality rates for the chosen diseases of affluence.
In the analysis below we have used some Spatial Statistics technics. Namely, local and global Moran's I statistics both uni-and bivariate ones.
The Moran's I statistic (Moran, 1947; Cliff, Ord, 1981 
The global Moran's I measures general regional similarity for all regions as a mean of local Moran's I i statistics. The global Moran's I statistic can be presented as follows: 
In the analysis below we considered the gross domestic product (GDP) at current market prices by NUTS 2 EU regions in the Purchasing Power Standard per inhabitant in the year 2011 and six crude death rate by the NUTS 2 EU region of residence caused by: diabetes mellitus, HIV, neoplasms, diseases of the circulatory system, mental and behavioural disorders, and socio-economic analyses of the regions and framing of EU regional policies. The NUTS 2 level is basic for the application of regional policies (Eurostat NUTS overview).
diseases of the respiratory system in the year 2011.
2 All spatial analysis are based on the queen contiguity spatial weight matrix, 1st order (Anselin, 1988 These still can be treated as some kind of indication of affluence -prevalence correlation.
In the next step of analysis, diseases of the circulatory system were considered. They the global effect is small but significant (see Figures 1, 2, 3 ). This actuality rather disproves the affluence hypothesis at least based on the mortality since prevalence data are not available.
Mental and behavioural disorders can be based on genetical and external factors. We can observe a concentration of death rates in regions of the Northern EU (Scandinavia and the UK).
Moran's I = 0.78 statistic indicates that there is high positive spatial autocorrelation of death rate caused by mental and behavioural disorders. Moreover, two clear clusters can be distinguished: The Global bivariate Moran's I = 0.54 indicates that the global spatial effect is strong and significant (see Figures 1, 2, 3 ). This again partly confirms the affluence character of diseases of the respiratory system, but rather with low prevalence in low-income regions.
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A spatial correlation analysis of mortality rates indicates that: (1) Germany has a cluster of high mortality rate regions with diabetes and cancer, (2) Italy has a cluster of high mortality rate regions for diabetes, HIV, and cancer, (3) the Iberian Peninsula has some clusters of high mortality rate regions for diabetes and diseases of the respiratory system but also a cluster of low mortality rates for diseases of the circulatory system, mental and behavioural disorders, and cancer, (4) the UK has a cluster of high mortality rate regions for cancer, mental and behavioural disorders, and diseases of the respiratory system but also a cluster of low mortality rates for diabetes, HIV, and diseases of the circulatory system, (5) Scandinavia has a cluster of high mortality rate regions for mental and behavioural disorders but also a cluster of low mortality rates for diabetes, HIV, and diseases of the respiratory system, (6) the Balkans have a cluster of high mortality rate regions for diseases of the circulatory system but also a cluster of low mortality rates for diabetes, HIV, cancer, mental and behavioural disorders, and diseases of the respiratory system, (7) Central Europe, with Poland, creates a cluster of low mortality rate regions for mental and behavioural disorders, and diseases of the respiratory system, (8) France has a cluster of low mortality rates for diseases of the circulatory system and diseases of the respiratory system.
In the case of high mortality in Germany, the UK, Scandinavia, Italy, the Iberian Peninsula as wealthy regions and on the other hand low mortality in the Balkans, Central Europe some diseases seem to prove the affluence hypothesis. The low mortality in France and Scandinavia does not disprove the hypothesis but simply suggests that the health care effect is stronger than any possible increase in the prevalence of illnesses.
Analysing the bivariate spatial correlation with GDP we can observe that: (1) Germany has some small clusters of regions with high mortality surrounded by regions with high GDP for every disease, (2) Central and Eastern Europe (the Balkans, Poland, Slovakia, Czech Republic, the Baltic States) create large clusters of regions with low mortality rates with high-GDP neighbouring regions for every illness except diseases of the circulatory system where almost the same cluster combines regions where high mortality borders with low GDP.
Thus, the affluence hypothesis may be true but in reverse: low-GDP regions have low mortality or prevalence or minor symptoms as for example Central and Eastern Europe. The only exception is a group of cardiovascular diseases which is a major problem in these poorer regions (probably due to traditional alcohol abuse and therefore unconnected to the GDP level).
Conclusions
Diseases of affluence are perceived as one the major risks of the 21st c. They are the cost of socioeconomic development and induced lifestyle changes. However, from the quantitative point of view, proving that economic progress is responsible for increasing the incidence rates is very difficult to establish. Especially that medical foundations do not clearly define the sources of these illnesses, leaving us with no obvious clue. Therefore, it would be valuable to conduct an exhaustive quantitative spatial analysis on the problem. Unfortunately, epidemiological statistics over time and space are scarce, which effectively hinders the desired research. The approach assumed in this paper is to analyse mortality rates instead of prevalence per se. This might be not a perfect proxy, however as the only possibility, we believe it can still lead to valuable and reliable conclusions.
In this paper an attempt at researching spatial patterns in Western diseases for European NUTS 2 has been made. Our results strongly suggest that some of the investigated diseases
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(like mental disorders, diseases of the respiratory system, neoplasms) have an established spatial pattern, and they are often correlated with the level of economic development. Although, some regions are more prone to the prevalence -development dependence (i.e. Central and Eastern Europe) than others. Our results may not be ultimate proof of the existence of diseases of affluence, but they do strongly suggest that some of the investigated diseases have an established spatial pattern, and they are often correlated with the level of economic development.
We believe that the methodology used is appropriate due to the spatial nature of the addressed problems. The link between economic development and the diseases of affluence at the regional level has been proven. The aim of the research has been fulfilled by the analysed data and the affluence hypothesis, although not omnipresent and omnipotent, have been proven to be plausible. Nevertheless, additional work needs to be done. The spatial Durbin model with spatially lagged GDP seems to be a good direction in any further analysis of this problem.
Therefore, we hope that this paper will increase the attention given to this topic by applying spatial econometric tools in the epidemiology of diseases of affluence.
